Clinical trials: Atopic Skin
Atopic Dermatitis Eczema
Skin Pathology Assessment With Optical Technologies
The Skin Pathology assessment with Optical Technologies (SPOT) study aims to assess the feasibility of recently developed light-based skin imaging tools such as Optical Coherence Tomography (OCT) for the study of eczema…
- Trial name
- SPOT (NCT04295824)
- Testing
- Skin imaging and Skin biopsy
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Atopic Dermatitis (AD), Psoriasis
A Clinical Evaluation of Marula-Derived Ceramide Cream on Skin Barrier Function Enhancement
Previously, the investigators have demonstrated in vitro the excellent efficacy of marula oil-derived ceramide NPs in enhancing skin barrier function.
- Conditions
- Atopic Dermatitis (AD), Psoriasis, Acne Vulgaris, Contact Dermatitis
- Trial name
- NCT07066150
- Testing
- Apply a cream containing 0.05% marula oil-derived ceramide NPs
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Shanghai Chicmax Cosmetic Co., Ltd.
Dermatitis, Atopic
Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD)
This clinical trial study is two-stage, multi-center, randomized, double-blind, placebo controlled, phase 3 clinical trial to evaluate the efficacy and safety of FURESTEM-AD Inj. for moderate to severe chronic atopic dermatitis.
- Trial name
- smart(FURIN) (NCT05004324)
- Testing
- FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL
- Where
- South Korea
- Volunteers
- 308 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis, Dermatitis, Atopic
Topical GW842470X In Adults Patients With Moderate Atopic Dermatitis
The purpose of this study is to investigate the clinical efficacy of 3% (w/w) GW842470X cream applied to involved skin of adult patients with moderate atopic dermatitis using the Eczema Area Severity Index (EASI) assessment of…
- Trial name
- NCT00354510
- Testing
- GW842470X cream
- Where
- 13 sites in Germany, Netherlands
- Volunteers
- 190 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects
A randomized, double-blind, placebo-controlled trial design was used to assess the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics, and immunogenicity of TQH2722 injection in healthy subjects.
- Trial name
- NCT05409326
- Testing
- TQH2722 injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Atopic Dermatitis
CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis
This is a phase III study to investigate the safety and efficacy of PAC-14028 cream in Atopic Dermatitis patients.
- Trial name
- NCT02965118
- Testing
- PAC-14028 cream 1.0%, PAC-14028 cream Vehicle
- Where
- South Korea
- Volunteers
- 240 people
- Sponsor
- Amorepacific Corporation
Atopic Dermatitis
Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp)
Atopic dermatitis (AD) is a common, chronic, inflammatory skin disease with a significant impact on patients' health-related quality of life.
- Trial name
- RAMpUp (NCT07741838)
- Volunteers
- 900 people
- Sponsor
- AbbVie
Dermatitis Atopic
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of…
- Trial name
- SHORE (NCT06224348)
- Testing
- Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitors
- Where
- 167 sites in United States, Argentina and 12 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Single-center, Randomized, Double-blinded, Placebo-controlled, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of NCP112
To evaluate safety, tolerability and pharmacokinetics of NCP 112 after single and multiple applications on the skin of healthy male volunteers.
- Trial name
- NCT05638165
- Testing
- NCP112
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- NovaCell Technology Inc.
Atopic Dermatitis
Efficacy of Acupuncture in the Treatment of Moderate-to-severe Atopic Dermatitis
This study used a multicentre parallel three-armed randomised sham-controlled clinical trial methodology in order to objectively and normatively assess the efficacy of acupuncture on Quchi the Sea of Blood the Foot Sanli and the…
- Trial name
- NCT06922565
- Testing
- acupuncture
- Volunteers
- 110 people
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Dermatologic Disease
Serotonin Levels in Atopic Dermatitis Patients
Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease of unknown aetiology. Global prevalence rates range from 1%-20%.AD is often worsened by stress and anxiety.Plasma levels of 5-HT were found to be positively…
- Trial name
- NCT03471819
- Testing
- Serum serotonin level
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Pruritus, Atopic Dermatitis
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
This is a two-part, multicenter, randomized, double-blind study to evaluate the efficacy and safety of oral difelikefalin as adjunct therapy to a topical corticosteroid (TCS) for moderate-to-severe pruritus in adult subjects with…
- Trial name
- KIND-1 (NCT05387707)
- Testing
- difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream
- Where
- 61 sites in United States
- Volunteers
- 287 people
- Sponsor
- Cara Therapeutics, Inc.
Severe Atopic Dermatitis
Long-term Study of Ciclosporin for Atopic Dermatitis
In patients with severe adult atopic dermatitis, the safety and efficacy of OL27-400MEPC will be assessed by repeating oral administration at a dose of 3 mg/kg/day (2-5 mg/kg/day) in 2 divided doses daily for 8-12 weeks and…
- Trial name
- NCT00232063
- Testing
- ciclosporin
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis
Seven-month study in pediatric patients (2-11 years) with moderate to severe AD who were considered to benefit from vaccination to prevent invasive disease caused by Neisseria meningitides serogroup C.
- Trial name
- NCT00801957
- Testing
- tacrolimus ointment 0.03%, hydrocortisone acetate ointment 1%, hydrocortisone butyrate ointment 0.1%
- Where
- 36 sites in Australia, Belgium and 6 more
- Volunteers
- 260 people
- Sponsor
- Astellas Pharma Inc
Eczema, Infantile, Eczema
Seal, Stopping Eczema and Allergy Study
This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age.
- Conditions
- Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
- Trial name
- NCT03742414
- Testing
- Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 398 people
- Sponsor
- Kari Nadeau, MD, PhD
Atopic Dermatitis
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients
Our hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease severity and favorably alters the function and gene expression of epidermal and immune skin cells that contribute to disease severity.
- Trial name
- NCT06397781
- Testing
- Skin Cleanser Combination No.1
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Boston Children's Hospital
Atopic Dermatitis
A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis
This is a multi-center, open-label phase 2 study to evaluate the long-term safety and efficacy of CM310 in subjects with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06116565
- Testing
- CM310
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis (AD)
Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis
This is a research study. The over-the-counter (OTC) drug for atopic dermatitis being tested is not approved as a treatment for the participants' atopic dermatitis condition.
- Trial name
- NCT07146971
- Testing
- OTC Drug for Atopic Dermatitis in Cream form
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Good Molecules, LLC
Atopic Dermatitis, House Dust Mite Allergy
Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients
The present study investigates the reaction of the skin upon exposure to house dust mite (HDM) in patients with atopic dermatitis who have antibodies against HDM in the blood.
- Trial name
- CODES (NCT05019209)
- Testing
- House Dust Mite Allergen, Allergen-free air
- Where
- 2 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Fraunhofer-Institute of Toxicology and Experimental Medicine
Atopic Dermatitis
Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis
This is a randomized, double-blind, single/multiple dose escalation, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in healthy subjects and…
- Trial name
- NCT06553209
- Testing
- CM512
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Keymed Biosciences Co.Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.